ABSTRACT
INTRODUCTION
Nucleic acid sequences can produce a wide variety of three-dimensional conformations. Some of these structural forms are able to interact with proteins and small molecules with high specificity and affinity. These sequences, comprising either doublestranded or single-stranded oligonucleotides, are called aptamers, based on the Latin word aptus , which means "to fit" (6) . Using an efficient selection process, randomized oligonucleotide libraries can be rapidly screened for aptamers with the appropriate binding characteristics (12) . This technology spawned the development of a new class of oligonucleotide therapeutic products and, although the interest among pharmaceutical companies continues to grow, there seems to be a reluctance to indulge the diagnostic potential of this technology. This may be due in part to the well-established use of monoclonal antibodies. Only recently is the literature beginning to reflect a growing emphasis on the potential for in vitro diagnostic use of aptamers (2, 5, 7, 8, 11) . While it would be difficult to predict the replacement of all existing immunodiagnostic approaches, aptamers could play a complementary role. In some assays, aptamers may successfully replace established immunological reagents, while in others they may be more appropriate in combination as capture or tracer elements of an immuno-oligonucleotide hybrid assay format. To prove DNA aptamers are versatile reagents for future use as in vitro diagnostic tools, we developed an immuno-oligonucleotide hybrid assay based on one of the most characterized aptamers to date, which has previously been shown to inhibit human thrombin activity (1).
MATERIALS AND METHODS

Thrombin Aptamer
All aptamers to human thrombin were obtained through Life Technologies (Rockville, MD, USA) custom synthesis service, according to the 15-mer G-quartet sequence 5 ′ -GGTTGGT -GTGGTTGG-3 ′ defined in previous reports (1, 10, 13) . This aptamer is known to bind to the active site on thrombin, thus inhibiting its activity. The aptamers were biotinylated at the 5 ′ end of the sequence by the Life Technologies custom synthesis service. Aptamers were purchased with and without 5 ′ extension of one, two, four, or six additional thymidine residues acting as a spacer arm (T-tail). Aptamers were reconstituted in TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) to obtain a 100-µ M solution and were stored at -20°C.
Thrombin Standards
Thrombin isolated from human plasma was obtained from Sigma (St. Louis, MO, USA) and was used diluted (10, 100, or 1000 ng/mL) in a high-protein assay buffer (A) containing 0.5% bovine serum albumin, 0.05% bovine IgG (Sigma-Aldrich, Oslo, Norway), 15 mg/L murine IgG1 (Roche Molecular Biochemicals, Mannheim, Germany), 50 mM Tris-HCl, pH 7.8, 0.15 M NaCl, 0.001% Triton ® X-100, 0.1% Germall, 0.02 mM diethylenetriaminepentaacetic acid (DTPA), and 0.005 g/L tatrazine. The incorporation of bovine and murine IgGs prevents assay interference from heterophilic antibodies.
Immuno-Oligonucleotide Hybrid Assay
A variety of different assay strategies were tested ( Table 1 ). The more traditional format using 96-well plates coated with the appropriate ligand (e.g., thrombin, aptamer, EST-7 antibody, and streptavidin) were notably unsuccessful. The following method incorporating immunomagnetic beads as the solid phase capture was the most appropriate strategy for this DNA aptamer.
Immunomagnetic beads of 280 nm particle size (Dynal, Oslo, Norway) were conjugated with sheep anti-mouse Ig, according to the manufacturer's instructions, then incubated with the IgG1 anti-αthrombin monoclonal antibody, EST-7 (American Diagnostica, Greenwich, CT, USA). This antibody is known to react with an epitope distant from the active site and was unlikely to hinder the binding of the labeled aptamer. The resulting EST-7-coated beads were washed three times in a protein-free assay buffer (B) containing 50 mM Tris-HCl, pH 7.8, 0.05% Tween ® 20, and 0.1% Germall.
The immunofluorometric aptamer assay was performed in 11 ×94 mm polyethylene tubes using a detachable magnetic rack system from Amersham Pharmacia Biotech (Little Chalfont, Bucks, UK). From the 100-µ M stock solution of aptamer, 5-60 µ L were added to the thrombin diluted in 450 µ L high-protein assay buffer (A). The mixture was incubated at 4°C for 2 h with vigorous shaking. After incubation, 100 µ L EST-7-coated magnetic beads (5 mg/mL) were added and incubated for another 30 min at room temperature with vigorous shaking. The tubes were placed in the magnetic rack and incubated for 10 min before discarding the supernatant. Tubes were removed from the magnet, facilitating the resuspension of the beads, then 0.7 mL assay buffer B was added. Tubes were replaced in the magnetic rack and incubated for 5 min. The wash cycle was repeated three times. After discarding the assay buffer from the final wash, 100 µ L europium (Eu)-labeled streptavidin (1 µ g/mL) were added and then incubated at room temperature for 30 min with vigorous shaking. The wash cycles were repeated six times before adding 200 µ L enhancing solution (Wallac, Turku, Finland), which releases the Eu3 + from the chelate. After incubating for 10 min, the tubes were replaced in the magnetic rack for another 5 min before transferring 180 µ L from each tube into a microplate. Plates were read by time-resolved fluorescence (1420 Multilabel Counter; Wallac). All assays were performed in triplicate. A variety of controls were tested to determine any interference from assay components or solid phases, including the omission of aptamer, thrombin, antibody, or Eu-neutralite from the assay. In addition, irrelevant antibody immunobeads were tested.
RESULTS AND DISCUSSION
Our approach, combining the use of aptamer and antibody in a hybrid immunofluorometric assay illustrates the versatility of DNA aptamers as diagnostic reagents. The strategy of using a magnetic bead solid phase in an immunofluorometric aptamer assay is novel and shows sensitivity for thrombin within physiological parameters (Figure 1) . The total measuring error (%CV ) of the assay was below 10% for thrombin concentrations up to 100 ng/mL. Moreover, the stringent assay conditions and high-protein content support previous data indicating the aptamer binds with high affinity to thrombin (13) . Interestingly, the sensitivity of our aptamer hybrid assay falls within the limits described in a recent report investigating thrombin levels as a prognostic marker in ovarian cancer patients (4) .
The 15-mer anti-thrombin DNA aptamer is well documented in the literature. It has binding affinity in the low nanomolar range and readily binds to thrombin, inhibiting fibrin clot formation in vitro (1) . The aptamer has been structurally characterized and has been shown to form a highly symmetrical Gquartet chair-like structure (10, 13) .
In our studies, successful binding was only observed in a very specific assay format (Table 1 , no. 5), suggesting the formation of the aptamer-thrombin complex in solution may be a prerequisite. That the comparable 96-well format assay (Table 1, no. 3) was unsuccessful further indicates that binding of this aptamer is sensitive to subtle variations in antigen presentation. One possible explanation could rest with the presentation of the EST-7 anti-thrombin antibody, which was directly bound to 96-well plates, while binding to beads was via an anti-mouse Ig. While this may reflect some general limitations in using aptamers in traditional 96-well assay formats, this feature may be more specific to the thrombin aptamer and/or aptamers with similar structural motifs. Indeed, nuclear magnetic resonance analysis has previously identified a specific G-quartet structure for this aptamer in solution (10) , which in practice may be more susceptible to solid-phase coupling. Nevertheless, a recent study indicated that immobilization of the thrombin aptamer via a shorter six-atom spacer to silicate beads did not interfere with thrombin binding (9) . Differences with the current study could be attributed to the different surface chemistries of the beads. Although there were no apparent differences in our assay performance for thrombin aptamers containing one, two, or four T residues in the T-tail, the use of six T residues had a significant impact (Figure 2) . It is not clear if these effects were the result of the proximity of biotin per se or if the length of the T-tail spacer contributed to a steric corruption of the aptamer's G-quartet structure. Similarly, these features may also be specific to the thrombin aptamer. Aptamers have been used in a variety of in vitro studies including enzymelinked oligonucleotide assay (5), flow cytometry (3), and direct binding (2, 11) . While this shows their versatility, our current findings also indicate that some aptamers may be more susceptible to assay conditions than their antibody counterparts or, indeed, other aptamers: the choice of solid phase used in an assay could significantly alter the aptamer conformation and hence the binding characteristics. Therefore, these factors need to be considered at an early stage in the selection process (12) , such that all the characteristics of a given aptamer are suitable for its intended end use, not just for its binding affinity. Indeed, a promising development along these lines is the synthesis and selection of photo-crossShort Technical Reports linkable aptamers that could be used as covalent capture reagents (2) . Our current findings demonstrate that the thrombin DNA aptamer is capable of binding to its target molecule under stringent in vitro assay conditions in the presence of high-protein and immunoglobulin concentration. This supports the view that DNA aptamers have potential value as complementary reagents in diagnostic assays.
